Atripla
valid: Two independent sources agree, or a primary source states it: the record asserts this claim.asserted
- Valid from
- undated
- Valid until
- still holds
- Published
- 2018-02-27
- Recorded by AsOf
- 2026-11-08
- Checked
- 2026-11-10 · its source page states the value and the date
- Confidence
- 0.80
Sources
“We may continue to purchase efavirenz from BMS as needed to continue manufacturing Atripla for the United States and Canada markets.”— what the page says, read 2026-11-10
- https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm
- https://www.wikidata.org/wiki/Q663596
Cite this claim
Plain text
AsOf. "Gilead Sciences produces: Atripla", undated. Claim clm_66A870C2CD56, https://asof.is/claim/clm_66A870C2CD56, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.
APA
AsOf. (n.d.). Gilead Sciences produces: Atripla (undated) [Record clm_66A870C2CD56]. Retrieved November 10, 2026, from https://asof.is/claim/clm_66A870C2CD56 (source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm)
BibTeX
@misc{asof_clm_66A870C2CD56,
author = {AsOf},
title = {Gilead Sciences produces: Atripla},
howpublished = {\url{https://asof.is/claim/clm_66A870C2CD56}},
note = {Claim clm\_66A870C2CD56, undated; source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm},
urldate = {2026-11-10}
}On the record
/claim/clm_66A870C2CD56.md/v1/claims/clm_66A870C2CD56submit a correction